Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab vs Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis (AMAGINE-2)
NCT01708603Phase 3Terminated
- Sponsor
- Valeant Pharmaceuticals
- Start
- Aug 2012
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of brodalumab in plaque psoriasis, sponsored by Valeant Pharmaceuticals. Started Aug 2012; status: terminated.
02
Drugs
brodalumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01708603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01708603.